Results 191 to 200 of about 47,423 (289)

From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity

open access: green, 2021
Mohammad Abdel‐Halim   +12 more
openalex   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post- and Precapillary Pulmonary Hypertension: A Propensity Score-Matched Analysis From the Hellenic Pulmonary Hypertension Registry. [PDF]

open access: yesPulm Circ
Papadopoulos GE   +15 more
europepmc   +1 more source

Elevated Salivary Theobromine and Long‐Term Improvement of Periodontal Health in Two Cohort Studies

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Background Theobromine, a methylxanthine mainly found in chocolate, has been suggested to possess various health‐promoting properties. This study aimed to investigate the long‐term effect of salivary theobromine levels on periodontitis severity using 7‐ and 10‐year follow‐up data from the prospective Studies of Health in Pomerania (SHIP‐TREND ...
Thomas Kocher   +8 more
wiley   +1 more source

Phosphodiesterase type 5 Inhibitors (PDE-5I) as a potential therapeutic drug in stroke: A systematic narrative review

open access: diamond, 2023
Harvey Sudharta   +5 more
openalex   +1 more source

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp   +5 more
wiley   +1 more source

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.

open access: yesJAMA Ophthalmol, 2022
Etminan M   +3 more
europepmc   +1 more source

Use of Phosphodiesterase 5 Inhibitors in Continuous-Flow Left Ventricular Assist Device Patients With Pulmonary: Hypertension: A Contemporary Analysis [PDF]

open access: bronze, 2015
Veli K. Topkara   +13 more
openalex   +1 more source

Home - About - Disclaimer - Privacy